RK-251: What we know about India’s new ‘smart’ cancer drug that ‘could replace chemotherapy’

India's researchers have developed a novel cancer drug called RK-251, which could potentially replace traditional chemotherapy. This "smart" drug is designed to remain inactive while traveling through the body, but it activates specifically inside cancer cells due to their higher levels of reactive oxygen species (ROS). Conventional chemotherapy affects both cancerous and healthy cells, leading to side effects.

The ROS-based approach of RK-251 could improve treatment selectivity by targeting cancer cells more precisely. Preclinical studies showed that RK-251 exhibits strong activity against aggressive triple-negative breast cancer cells while having minimal impact on healthy cells. Researchers also tested the drug in zebrafish embryos and found no obvious signs of toxicity.

However, these findings are still in the preclinical stage, and more studies are needed to establish its safety, appropriate dosing, behavior in the human body, and potential for meaningful tumor responses. While RK-251 shows promise, it is unlikely to completely replace chemotherapy, as it would be another option in the cancer treatment realm.

Before it can be tested in patients, researchers must address these hurdles to validate its effectiveness and safety.